JP2024516376A5 - - Google Patents
Info
- Publication number
- JP2024516376A5 JP2024516376A5 JP2023563189A JP2023563189A JP2024516376A5 JP 2024516376 A5 JP2024516376 A5 JP 2024516376A5 JP 2023563189 A JP2023563189 A JP 2023563189A JP 2023563189 A JP2023563189 A JP 2023563189A JP 2024516376 A5 JP2024516376 A5 JP 2024516376A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176225P | 2021-04-17 | 2021-04-17 | |
| US63/176,225 | 2021-04-17 | ||
| PCT/US2022/025075 WO2022221696A1 (en) | 2021-04-17 | 2022-04-15 | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024516376A JP2024516376A (ja) | 2024-04-15 |
| JPWO2022221696A5 JPWO2022221696A5 (https=) | 2025-04-22 |
| JP2024516376A5 true JP2024516376A5 (https=) | 2025-04-22 |
Family
ID=81581217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563189A Pending JP2024516376A (ja) | 2021-04-17 | 2022-04-15 | Ｄｎａ依存性プロテインキナーゼの阻害剤ならびにその組成物及び使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240300977A1 (https=) |
| EP (1) | EP4323360A1 (https=) |
| JP (1) | JP2024516376A (https=) |
| KR (1) | KR20240017791A (https=) |
| CN (1) | CN117940426A (https=) |
| AU (1) | AU2022258733A1 (https=) |
| BR (1) | BR112023021429A2 (https=) |
| CA (1) | CA3216875A1 (https=) |
| CL (1) | CL2023003079A1 (https=) |
| CO (1) | CO2023015478A2 (https=) |
| CR (1) | CR20230535A (https=) |
| IL (1) | IL307740A (https=) |
| MX (1) | MX2023012236A (https=) |
| TW (1) | TW202309034A (https=) |
| WO (1) | WO2022221696A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US20250305004A1 (en) * | 2022-05-13 | 2025-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment |
| TW202440086A (zh) * | 2023-03-13 | 2024-10-16 | 美商英塞特公司 | 作為激酶抑制劑之雙環脲 |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025049432A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137301A1 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
| GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| WO2011091324A2 (en) | 2010-01-22 | 2011-07-28 | The Scripps Research Institute | Methods of generating zinc finger nucleases having altered activity |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| ES2895651T3 (es) | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| SMT202100225T1 (it) | 2016-12-20 | 2021-05-07 | Astrazeneca Ab | Composti di ammino-triazolopiridina e loro uso nel trattamento del cancro |
| PT3688162T (pt) | 2017-09-29 | 2024-04-23 | Intellia Therapeutics Inc | Formulações |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| WO2020072605A1 (en) | 2018-10-02 | 2020-04-09 | Intellia Therapeutics, Inc. | Ionizable amine lipids |
| IL314386A (en) | 2018-12-05 | 2024-09-01 | Intellia Therapeutics Inc | amine modified lipids |
| WO2020219876A1 (en) | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
| WO2020257325A1 (en) * | 2019-06-17 | 2020-12-24 | Vertex Pharmaceuticals Inc. | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
-
2022
- 2022-04-15 CR CR20230535A patent/CR20230535A/es unknown
- 2022-04-15 IL IL307740A patent/IL307740A/en unknown
- 2022-04-15 BR BR112023021429A patent/BR112023021429A2/pt not_active Application Discontinuation
- 2022-04-15 TW TW111114469A patent/TW202309034A/zh unknown
- 2022-04-15 KR KR1020237039428A patent/KR20240017791A/ko active Pending
- 2022-04-15 JP JP2023563189A patent/JP2024516376A/ja active Pending
- 2022-04-15 MX MX2023012236A patent/MX2023012236A/es unknown
- 2022-04-15 EP EP22721588.6A patent/EP4323360A1/en active Pending
- 2022-04-15 WO PCT/US2022/025075 patent/WO2022221696A1/en not_active Ceased
- 2022-04-15 CN CN202280042815.9A patent/CN117940426A/zh active Pending
- 2022-04-15 AU AU2022258733A patent/AU2022258733A1/en active Pending
- 2022-04-15 CA CA3216875A patent/CA3216875A1/en active Pending
- 2022-04-15 US US18/287,227 patent/US20240300977A1/en active Pending
-
2023
- 2023-10-16 CL CL2023003079A patent/CL2023003079A1/es unknown
- 2023-11-16 CO CONC2023/0015478A patent/CO2023015478A2/es unknown